Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00042250 |
To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.
Condition | Intervention |
---|---|
Hematologic Malignancies |
Drug: Chemotherapy for hematologic malignancy |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study |
Official Title: | Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Histologic proof of one of:
Participants should be:
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Study Chair: | Michael Andreeff, MD, PhD | U. T. M. D. Anderson Cancer Center |
Study ID Numbers: | DM91-102 |
Study First Received: | July 24, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00042250 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Cell Cycle Interphase G0 G1 G2 S Phase |
Bromodeoxyuridine Hematologic Neoplasms Hematologic Diseases Idoxuridine |
Neoplasms Neoplasms by Site Hematologic Neoplasms Hematologic Diseases |